The Tour de Cure, initiated by the BC Cancer Foundation, is a challenging and inspiring cycling fundraising event that brings together thousands of cyclists to pedal for a cause. This year, more than 1,500 riders participated. It rained heavily on the first day, and this ride was a big challenge for everyone.
“The riding yesterday was incredibly wet, the toughest I’ve ever experienced. It was a true test of our abilities,” said Karsten, Captain of Siu Team 6. “We are happy that we pushed through.”
Ruth, office manager at Redsenol and a member of Siu Team 6, shared her personal motivation for participating: “It’s an honor to contribute to cancer research and support patients in their journey. Completing the 200-kilometer ride is a small but meaningful step towards making a difference.”
“We are proud of Siu Team 6 for finishing the riding. It is an honor for us to be a part of this significant event,” said Dr. Peihua Yu, Redsenol’s CEO. “We are having a clinical trial underway, and we are excited about the potential success of this trial and the positive impact it could have on cancer patients.”
Redsenol has been at the forefront of research into small molecule compounds, aiming to provide effective health solutions to cancer patients. The clinical trial for Redsenol-1 Plus Noble Ginsenoside capsules, containing sixteen exceptionally bioactive and easily absorbable small molecule rare ginsenosides, is currently in progress. The successful outcome of this trial is poised to deliver groundbreaking solutions for cancer-related fatigue.
